Results 11 to 20 of about 869,643 (295)

Biotechnological applications of recombinant single-domain antibody fragments [PDF]

open access: yesMicrobial Cell Factories, 2011
Background Single-domain antibody fragments possess structural features, such as a small dimension, an elevated stability, and the singularity of recognizing epitopes non-accessible for conventional antibodies that make them interesting for several ...
de Marco Ario
doaj   +3 more sources

Single-domain antibodies make a difference [PDF]

open access: yesScience, 2021
A double hit with one antibody construct may avoid viral ...
Xavier, Saelens, Bert, Schepens
openaire   +2 more sources

Immunogenicity and humanization of single‐domain antibodies [PDF]

open access: yesThe FEBS Journal, 2021
Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy‐chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development ...
Rossotti, Martin A.   +3 more
openaire   +2 more sources

Single-domain antibodies for biomedical applications [PDF]

open access: yesImmunopharmacology and Immunotoxicology, 2015
Single-domain antibodies are the smallest antigen-binding units of antibodies, consisting either only of one variable domain or one engineered constant domain that solely facilitates target binding. This class of antibody derivatives comprises naturally occurring variable domains derived from camelids and sharks as well as engineered human variable or ...
Krah, Simon   +5 more
openaire   +3 more sources

Selective engagement of FcγRIV by a M2e-specific single domain antibody construct protects against influenza A virus infection [PDF]

open access: yes, 2019
Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as well as pandemic influenza A.
Ballegeer, Marlies   +10 more
core   +2 more sources

Bglbrick strategy for the construction of single domain antibody fusions

open access: yesHeliyon, 2017
Single domain antibodies, recombinantly expressed variable domains derived from camelid heavy chain antibodies, are often expressed as multimers for detection and therapeutic applications.
Ellen R. Goldman   +3 more
doaj   +1 more source

mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice

open access: yesMolecular Therapy: Nucleic Acids, 2020
To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant ...
Lien Van Hoecke   +10 more
doaj   +1 more source

A Human-Derived Monoclonal Antibody Targeting Extracellular Connexin Domain Selectively Modulates Hemichannel Function [PDF]

open access: yes, 2019
Connexin hemichannels, which are plasma membrane hexameric channels (connexons) composed of connexin protein protomers, have been implicated in a host of physiological processes and pathological conditions. A number of single point pathological mutations
Buratto, Damiano   +12 more
core   +1 more source

Single-Domain Antibody Theranostics on the Horizon. [PDF]

open access: yesJ Nucl Med, 2022
Single-domain antibody (sdAb) is among the most promising vectors for developing molecular imaging tracers. Several sdAb tracers targeting human epidermal growth factor receptor 2 or programmed death ligand 1 have entered clinical practice. However, radiolabeled single-valent sdAbs generally have high kidney retention, limiting their therapeutic ...
Wei W, Younis MH, Lan X, Liu J, Cai W.
europepmc   +3 more sources

Photobodies: Light‐Activatable Single‐Domain Antibody Fragments [PDF]

open access: yesAngewandte Chemie, 2019
AbstractPhotocaged antibody fragments, termed photobodies, have been developed that are impaired in their antigen‐binding capacity and can be activated by irradiation with UV light (365 nm). This rational design concept builds on the selective photocaging of a single tyrosine in a nanobody (a single‐domain antibody fragment).
Benedikt Jedlitzke   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy